Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1697-1706

  Rao, Gauri ^a   Iyer, Vandana ^a   Kosloski, Matthew P ^a   Pisal, Dipak S ^a   Shin, Eunkyoung ^a   Middaugh, C Russell ^b   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Formulation and stability; Lumry Eyring nucleated polymerization model; Monoclonal antibody therapeutics; Unfolding

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; MONOMER; UNCLASSIFIED DRUG;

ARTICLE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; FLUORESCENCE SPECTROSCOPY; NONHUMAN; OLIGOMERIZATION; PHASE TRANSITION; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; STEADY STATE; TEMPERATURE STRESS; THERMODYNAMICS; TURBIDITY; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 77949812737     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21938     Document Type: Article

References (16)

1. Usami A, Ohtsu A, Takahama S, Fujii T. 1996. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J Pharm Biomed Anal 14:1133-1140.
2. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96:1-26.
3. Harn N, Allan C, Oliver C, Middaugh CR. 2007. Highly concentrated monoclonal antibody solutions: Direct analysis of physical structure and thermal stability. J Pharm Sci 96:532-546.
4. Kindt TJ, Goldsby RA, Osborne BA. 2007. Immunology. 6th edition, New York: W.H. Freeman and Co.
5. Andrews JM, Roberts CJ. 2007. Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. Biochemistry 46:7558-7571.
6. Ramani K, Purohit V, Middaugh CR, Balasubramanian SV. 2005. Aggregation kinetics of recombinant human FVIII (rFVIII). J Pharm Sci 94:2023-2029.
7. Vermeer AW, Norde W. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78:394-404.
8. Ptitsyn OB, Pain RH, Semisotnov GV, Zerovnik E, Razgulyaev OI. 1990. Evidence for a molten globule state as a general intermediate in protein folding. FEBS Lett 262:20-24.
9. Balasubramanian SV, Bruenn J, Straubinger RM. 2000. Liposomes as formulation excipients for protein pharmaceuticals: A model protein study. Pharm Res 17:344-350.
10. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing.AAPSJ 8:E572-579.
11. Sanchez-Ruiz JM, Lopez-Lacomba JL, Cortijo M, Mateo PL. 1988. Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin. Biochemistry 27:1648-1652.
12. McGoff PG. In: McGoff PG, Scher DS, editors. 2000. Solution formulation of proteins and peptides. Vol. 99, New York: Marcel Dekkar.
13. Andrews JM, Roberts CJ. 2007. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J Phys Chem B 111:7897-7913.
14. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97:1414-1426.
15. Weiss WFT, Young TM, Roberts CJ. 2008. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 98:1246-1277.
16. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2008. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98:1201-1205.